Quizartinib has recently been approved by FDA for the combination treatment with standard cytarabine and anthracycline induction and consolidation therapy and as maintenance monotherapy following consolidation chemotherapy for the treatment of adult patients with newly diagnosed AML with FLT3/ITD mutation [11]. Here, FLT3 is linked to acute myeloid leukemia.